Skip to main content
Premium Trial:

Request an Annual Quote

Epigenetic Biomarker Firm Foxo Technologies Raises $10M

NEW YORK — Epigenetic biomarker developer Foxo Technologies said on Wednesday that it has raised $10 million in private financing.

The investment round was led by Bespoke Growth Partners and brings Foxo's total amount of funding raised to date to $40 million, the Minneapolis-based company said.

Foxo said it will use the money to continue developing its bioinformatics and DNA microarray technologies for identifying epigenetic biomarkers of health and aging. The company currently offers biomarker discovery using Illumina Infinium Human and Infinium Mouse Methylation Arrays for DNA methylation testing and its MethylSuite software for epigenetic data analysis. The company is also preparing to launch a life insurance service called Foxo Life.

"The maturation of DNA sequencing technology platforms coupled with [artificial intelligence] and bioinformatic tools is creating a new era in the science of health and wellness," Foxo Founder and CEO Jon Sabes said in a statement. "We are harnessing these technologies to create proprietary, hyper-personalized epigenetic biomarkers of health and wellness that work synergistically with life insurance."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.